NL
DE
25 July 2018
In a 4-year program MWH4impact financially supports specialized staff to enable the “market-readiness” of the promising Natural Killer (NK) cell therapy product developed in the Radboudumc. This involves the upscaling and implementation strategy of an off-the-shelf NK cell product generated from umbilical cord blood stem cells.
Harry Dolstra, (photo above), Joop Jansen and their team, theme Cancer development and immune defense, have succeeded in growing these NK cells from stem cells in large numbers. They received grants from KWF to examine in patients whether these NK cells can effectively combat leukemia and ovarian cancer cells. Together with MWH4impact they are in an unique position to further develop and bring the NK cell therapy to patients with cancer.
The Departments of Laboratory Medicine and Hematology entered into a partnership with the Social impact foundation MWH4impact on Natural Killer cell therapy.
In a 4-year program MWH4impact financially supports specialized staff to enable the “market-readiness” of the promising Natural Killer (NK) cell therapy product developed in the Radboudumc. This involves the upscaling and implementation strategy of an off-the-shelf NK cell product generated from umbilical cord blood stem cells.
Harry Dolstra, (photo above), Joop Jansen and their team, theme Cancer development and immune defense, have succeeded in growing these NK cells from stem cells in large numbers. They received grants from KWF to examine in patients whether these NK cells can effectively combat leukemia and ovarian cancer cells. Together with MWH4impact they are in an unique position to further develop and bring the NK cell therapy to patients with cancer.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Dutch Society of Clinical Chemistry Science & Innovation Award for the team of Hans Jacobs
14 June 2022 The team of Hans Jacobs pioneers on the development of personalized diagnostics to measure minimal residual disease in patients with multiple myeloma. read more
2.5 million Euros for cancer research into ovarian cancer and immunotherapy
15 April 2021 The Radboudumc receives 2.5 million Euros from the Dutch Cancer Society (KWF) for three studies to ensure oncological progress during COVID-19 period. read more
RIMLS PhD grants awarded to eight RIMLS (j)PI's
12 September 2019 Recently, RIMLS held an internal call for Radboudumc junior researcher (PhD) positions. Congratulations for all the awardees and all the best in conducting the research projects. read more
Two papers on molecular mechanisms of GFI1B in inherited bleeding syndromes in Haematologica
21 January 2019 Rinske van Oorschot from the Van der Reijden group, theme Cancer development and immune defense, has published two papers on the transcription factor GFI1B in Haematologica. read more
RIMLS awards festival Twelve winners
16 January 2019 In 5 categories RIMLS young researchers received an award and bonus during the New Year's drinks. See all photo's. read more
